science

List of investigational agitation drugs

List of investigational agitation drugs is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand List of investigational agitation drugs rather than just read about it. In short: This is a list of investigational agitation drugs, or drugs that are currently under development for clinical use in the treatment of agitation, for instance in people with dementia or autism, but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

Key takeaways

List of investigational agitation drugs belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect List of investigational agitation drugs to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of List of investigational agitation drugs from memory before moving on to harder problems.

Reference excerpt

This is a list of investigational agitation drugs, or drugs that are currently under development for clinical use in the treatment of agitation, for instance in people with dementia or autism, but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in February 2025. It is likely to become outdated with time.

Under development

Phase 3 Aripiprazole (Abilify) – atypical antipsychotic (non-selective monoamine receptor modulator) Deudextromethorphan/quinidine (AVP-786; CTP-786; d-DM) – sigma σ1 receptor agonist, serotonin reuptake inhibitor, ionotropic glutamate NMDA receptor antagonist, other actions, and CYP2D6 inhibitor combination Masupirdine (SUVN502; SVN-502) – serotonin 5-HT6 receptor antagonist

Phase 2/3 Deramciclane (EXV-801) – serotonin 5-HT2A receptor antagonist, serotonin 5-HT2C receptor inverse agonist, GABA reuptake inhibitor, and weak CYP2D6 inhibitor Deramciclane/dextromethorphan (EXV-802; Deraphan) combination of deramciclane (serotonin 5-HT2A receptor antagonist, serotonin 5-HT2C receptor inverse agonist, GABA reuptake inhibitor, and weak CYP2D6 inhibitor) and dextromethorphan (sigma σ1 receptor agonist, serotonin reuptake inhibitor, ionotropic glutamate NMDA receptor antagonist, other actions)

Phase 2 Cyclobenzaprine (KRL-102; TNX-102; Tonmya) – tricyclic antidepressant (monoamine reuptake inhibitor and monoamine receptor modulator) Deulumateperone (ITI-1284; lumateperone deuterated) – atypical antipsychotic (non-selective monoamine receptor modulator) Dexmedetomidine transdermal patch (DMTS; TPU-006) – α2-adrenergic receptor agonist Dronabinol/palmidrol (THC/PEA; SCI-110; THX OSA01; THX RS01; THX-110; THX-TS01) – cannabinoid receptor modulator and other actions combination Irafamdastat (BMS-986368; CC-97489) – dual fatty acid amide hydrolase (FAAH) inhibitor and monoacylglycerol lipase (MAGL) inhibitor KNX-100 (SOC-1) – 15-lipoxygenase (15-LOX; ALOX15) inhibitor and oxytocin-like drug or indirect oxytocin receptor modulator [1] [2] ONO-2020 – immunomodulator and inflammation modulator – specifically for agitation in Alzheimer's disease Pimavanserin (ACP-103; BVF-048; Nuplazid) – serotonin 5-HT2A receptor antagonist/inverse agonist SAL-0114 – undefined mechanism of action Soclenicant (BNC-210; IW-2143; L-isoleucyl-L-tryptophan) – α7 nicotinic acetylcholine receptor negative allosteric modulator

Phase 1 Dexmedetomidine sublingual (iXB-120) – α2-adrenergic receptor agonist NMRA-511 (BTRX-323511; NMRA-323511) – vasopressin V1A receptor antagonist SEP-380135 – undefined mechanism of action

Preclinical KNX-101 – 15-lipoxygenase (15-LOX; ALOX15) inhibitor

Not under development

No development reported Cannabidiol (RLS-102) – cannabinoid receptor modulator Scyllo-inositol – β-amyloid inhibitor – specifically for agitation in Alzheimer's disease Zolmitriptan (ML-004) – serotonin 5-HT1B and 5-HT1D receptor agonist

Suspended Latrepirdine (BXCL-502) – various actions

Discontinued ALKS-7119 ((9α,13α)-17-methylmorphinan-3-carboxamide; dextromethorphan analogue) – serotonin reuptake inhibitor and μ-opioid, α1A-adrenergic, α1B-adrenergic, NMDA, and sigma σ1 receptor modulator Dextromethorphan/quinidine (AVP-923; Neurodex; Nuedexta; Zenvia) – sigma σ1 receptor agonist, serotonin reuptake inhibitor, ionotropic glutamate NMDA receptor antagonist, other actions, and CYP2D6 inhibitor combination Mibampator (LY-451395) – ionotropic glutamate AMPA receptor positive allosteric modulator Olanzapine intranasal (INP-105; POD™ olanzapine) – atypical antipsychotic (non-selective monoamine receptor modulator)

Clinically used drugs

Approved drugs

Antipsychotics Brexpiprazole (Rexulti) – atypical antipsychotic (non-selective monoamine receptor modulator) Loxapine inhalation (Adasuve; ALXZ-004; AZ-004; Staccato Loxapine) – antipsychotic (non-selective monoamine receptor modulator) Paliperidone (Invega) – atypical antipsychotic (non-selective monoamine receptor modulator)

Others Bupropion/dextromethorphan (AXS-05; Auvelity) – sigma σ1 receptor agonist, serotonin reuptake inhibitor, norepinephrine and dopamine reuptake inhibitor, nicotinic acetylcholine receptor negative allosteric modulator, ionotropic glutamate NMDA receptor antagonist, other actions, and CYP2D6 inhibitor combination Dexmedetomidine (Igalmi) – α2-adrenergic receptor agonist

Off-label drugs Benzodiazepines (GABAA receptor positive allosteric modulators) (e.g., diazepam, lorazepam, midazolam) Beta blockers (β-adrenergic receptor antagonists) (e.g., propranolol, pindolol, nadolol) Cannabinoids (cannabinoid receptor agonists) (e.g., cannabis, dronabinol, nabilone) Dissociative anesthetics (NMDA receptor antagonists) (e.g., ketamine)

See also List of investigational drugs List of investigational aggression drugs List of investigational antipsychotics List of investigational autism and pervasive developmental disorder drugs

References

External links AdisInsight - Springer

Worked examples

Example 1 — a first encounter with List of investigational agitation drugs

Start with the simplest possible case. Write down what List of investigational agitation drugs claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to List of investigational agitation drugs before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about List of investigational agitation drugs ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of List of investigational agitation drugs

In research: List of investigational agitation drugs appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses List of investigational agitation drugs in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: List of investigational agitation drugs is common in secondary-school and first-year university syllabi. It links to neighbouring topics Experimental psychiatric drugs, Lists of investigational drugs, so understanding it makes those chapters shorter.
In everyday life: Look for List of investigational agitation drugs outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “List of investigational agitation drugs” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study List of investigational agitation drugs in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what List of investigational agitation drugs means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain List of investigational agitation drugs out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is List of investigational agitation drugs in simple terms?

Why does List of investigational agitation drugs matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study List of investigational agitation drugs?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on List of investigational agitation drugs.